TLR4 and cardiac hypertrophy: Previously, it was reported that inhibition of mTOR by rapamycin attenuates pathological hypertrophic response by downregulating NF-κB signaling (93), whereas rapamycin has an additional improvement for cardiac hypertrophy in TLR4 deficient mice (23).